Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Atrium TherapeuticsRNA -0.16%12 Earnings Yield (Joel Greenblatt) % is 178.57% as of Mar. 2026, which is 1% above its 10-year median of 176.40. GuruFocus rates RNA with a GF Score™ of 12/100. The stock has 1 warning sign investors should review. Among 1,331 Biotechnology companies, Atrium Therapeutics ranks worse than 75131.4% on this metric.
Atrium Therapeutics's Enterprise Value for the quarter that ended in Mar. 2026 was $-36.46 Mil.
Atrium Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was $-65.32 Mil. Atrium Therapeutics's Earnings Yield (Joel Greenblatt) for the quarter that ended in Mar. 2026 was 178.57%.
The historical rank and industry rank for Atrium Therapeutics's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:
RNA'
s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: 113.64 Med: 176.4 Max: 481.69
Current: 113.64
During the past 3 years, the highest Earnings Yield (Joel Greenblatt) of Atrium Therapeutics was 481.69%. The lowest was 113.64%. And the median was 176.40%.
RNA's Earnings Yield (Joel Greenblatt) % is not ranked
in the Biotechnology industry.
Industry Median: -10.03
vs RNA: 113.64
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. Atrium Therapeutics's Forward Rate of Return (Yacktman) % for the quarter that ended in Mar. 2026 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past five years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.
Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.
Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.
Be Aware
Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.
Atrium Therapeutics Earnings Yield (Joel Greenblatt) % Related Terms
Atrium Therapeutics Earnings Yield (Joel Greenblatt) % Historical Data
* Premium members only.
The historical data trend for Atrium Therapeutics's Earnings Yield (Joel Greenblatt) % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Atrium Therapeutics's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Atrium Therapeutics Earnings Yield (Joel Greenblatt) % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Atrium Therapeutics's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where Atrium Therapeutics's Earnings Yield (Joel Greenblatt) % falls into.
In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.
Atrium Therapeuticss Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2025 is calculated as
Atrium Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-65.32 Mil.
What does a Earnings Yield (Joel Greenblatt) % of 178.57% mean?
Atrium Therapeutics (RNA) has a Earnings Yield (Joel Greenblatt) % of 178.57% as of Mar. 2026. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Atrium Therapeutics and its competitors. This is near median its historical median of 176.40. Over the past decade, Atrium Therapeutics' Earnings Yield (Joel Greenblatt) % has ranged from 113.64 to 481.69. According to the industry distribution chart, Atrium Therapeutics ranks #999999 out of 1331 companies in the Biotechnology industry.
Is Atrium Therapeutics' Earnings Yield (Joel Greenblatt) % too high?
Atrium Therapeutics' current Earnings Yield (Joel Greenblatt) % of 178.57% is near median its 10-year median of 176.40. Over the past 10 years, this metric has ranged from a low of 113.64 to a high of 481.69. Based on the distribution chart, Atrium Therapeutics ranks #999999 out of 1331 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Atrium Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Atrium Therapeutics' Earnings Yield (Joel Greenblatt) % compare to CNTN and QTTB?
According to the Biotechnology industry distribution chart, Atrium Therapeutics ranks #999999 out of 1331 companies for Earnings Yield (Joel Greenblatt) %. This places Atrium Therapeutics in the lower half of its industry. Historically, Atrium Therapeutics' own Earnings Yield (Joel Greenblatt) % has ranged from 113.64 to 481.69 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Yield (Joel Greenblatt) % for a Biotechnology company?
A good Earnings Yield (Joel Greenblatt) % depends on the Biotechnology industry context. However, Earnings Yield (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Yield (Joel Greenblatt) % mean?
A high Earnings Yield (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's earnings yield equals the ratio of earnings before interest and taxes to enterprise value. View historical data on Atrium Therapeutics and its competitors. Atrium Therapeutics's current Earnings Yield (Joel Greenblatt) % is 178.57%, which is near median its own 10-year median of 176.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atrium Therapeutics stock overvalued right now?
Atrium Therapeutics (RNA) has a current Earnings Yield (Joel Greenblatt) % of 178.57%. The current Earnings Yield (Joel Greenblatt) % is 178.57%, which is near median its 10-year median of 176.40. Atrium Therapeutics' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Yield (Joel Greenblatt) % calculated?
Earnings Yield (Joel Greenblatt) % is calculated from a company's financial statements. For Atrium Therapeutics (RNA), the current Earnings Yield (Joel Greenblatt) % is 178.57% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Address10578 Science Center Drive, Suite 125, San Diego, CA, USA, 92121
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.
12GF Score
Get the complete analysis for RNA
Earnings Yield (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RNA has been successfully added to your 
